AstraZeneca & Daiichi Sankyo to develop new antibody drug conjugate

AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo to develop and commercialise a new antibody drug conjugate.

Under the agreement, the two companies will develop and commercialise DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment of multiple tumour types.

DS-1062 is currently in development for the treatment of multiple tumours that commonly express the cell-surface glycoprotein TROP2. Among them, TROP2 is overexpressed in the majority of non-small cell lung cancers1 and breast cancers, tumour types that have long been a strategic focus for AstraZeneca.

This collaboration reflects AstraZeneca’s strategy to invest in antibody drug conjugates as a class, the innovative nature of the technology and the successful existing collaboration with Daiichi Sankyo.

“We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express TROP2,” said AstraZeneca CEO Pascal Soriot.

“We are delighted to enter this new collaboration with Daiichi Sankyo and to build on the successful launch of Enhertu to further expand our pipeline and leadership in Oncology.

“We now have six potential blockbusters in Oncology with more to come in our early and late pipelines.”

Sunao Manabe, Representative Director, President and CEO of Daiichi Sankyo, said: “DS-1062, one of our lead DXd ADCs that will form a pillar of our next mid-term business plan, has the potential to become a best-in-class TROP2 ADC in multiple tumours, including lung and breast cancers.

“This new strategic collaboration with AstraZeneca, a company with extensive experience and significant expertise in the global oncology business, will enable us to deliver DS-1062 to more patients around the world as quickly as possible.

“As we have done with Enhertu, we will jointly design and implement strategies to maximise the value of DS-1062.”

Using Daiichi Sankyo’s proprietary DXd ADC technology, DS-1062 is designed to deliver chemotherapy selectively to cancer cells and to reduce systemic exposure. A comprehensive development programme with DS-1062 is planned globally.

AstraZeneca will pay Daiichi Sankyo an upfront payment of $1bn in staged payments: $350m is due upon completion, with $325 million after 12 months and $325 million after 24 months from the effective date of the agreement.

AstraZeneca will pay additional conditional amounts of up to $1 billion for the successful achievement of regulatory approvals and up to $4 billion for sales-related milestones.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Celltrion given the go-ahead for anti-COVID-19 antibody trial

Celltrion’s Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has been approved...

Related news

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...